Resverlogix CorpShs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.01.22	Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment (GlobeNewswire)
03.11.21	Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients (GlobeNewswire)
01.11.21	Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone (GlobeNewswire)
03.06.21	Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada (GlobeNewswire)
12.04.21	Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19 (GlobeNewswire)
26.10.20	A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms (GlobeNewswire)
14.10.20	Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet (GlobeNewswire)
18.04.19	Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events (GlobeNewswire)
07.08.18	Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone (GlobeNewswire)
31.07.18	Resverlogix Intends to Pursue U.S. Listing (GlobeNewswire)
14.06.18	Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone (GlobeNewswire)
07.06.18	Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the "Shock and Kill" Approach (GlobeNewswire)
25.05.18	Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress (GlobeNewswire)
19.03.18	Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial (GlobeNewswire)
08.01.18	Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement (GlobeNewswire)
12.12.17	Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1 (GlobeNewswire)
04.12.17	Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink (GlobeNewswire)
29.08.17	Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial (PR Newswire)
25.07.17	Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial (PR Newswire)
10.07.17	Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial (PR Newswire)
31.05.17	Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain (PR Newswire)
30.05.17	Resverlogix Receives Approval From Health Canada to Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone (PR Newswire)
23.05.17	Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success (PR Newswire)
15.05.17	Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial (PR Newswire)
23.01.17	Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Resverlogix CorpShs

Aktien Top/Flop

Meistgelesene Nachrichten